Development of VLP vaccine for RSV

Ended Project Grant Awarded Last action

Award ID
R44AI109926
Recipient
Awarding agency
Obligated
$5,419,498

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Funding
  • $4,419,497.84 Federal
  • $1,000,000.00 Non-federal
Place of performance
Rockville, MD 20850, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment Development of VLP vaccine for RSV - the sars-COV-2 responsible for the coronavirus disease 2019 (covid-2019) outbreak represents a major public health threat… -$57,477 $0
Amendment Development of VLP vaccine for RSV - respiratory syncytial virus (RSV) is a significant human pathogen severely impacting neonates and young children, but no… $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,000,000 $0
Amendment Development of VLP vaccine for RSV - the sars-COV-2 responsible for the coronavirus disease 2019 (covid-2019) outbreak represents a major public health threat… $1,000,000 $1,000,000
Amendment $476,975 $0
Amendment $1,000,000 $0
Original award $1,000,000 $0
Show all 12

Quick answers

Who received award R44AI109926?

R44AI109926 was awarded to Sigmovir Biosystems, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 21, 2020.

How much is award R44AI109926 worth?

$5,419,498 has been obligated on R44AI109926: $4,419,498 in federal funding and $1,000,000 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award